Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep is a biotechnology company with a promising product pipeline and a strong financial position, making it a favorable investment opportunity. The clinical trials for its lead drug candidate efti have shown positive results in treating various types of cancer, and its unique mechanism of action sets it apart from other treatments. The company's experienced leadership and multiple ongoing studies add to its potential for success.

Bears say

Immutep is a late-stage clinical biotechnology company with a diversified product portfolio focused on developing novel immunotherapies for cancer and autoimmune diseases, using LAG-3's immune response capabilities. However, the company's potential success relies heavily on its lead product candidate, eftilagimod alfa (efti), which is currently in a registrational Phase 3 trial for first-line non-small cell lung cancer (NSCLC). Despite positive data in other indications, there are still unresolved questions about efti's efficacy and mechanism of action, as well as potential competition in the PD-L1-positive patient population. Moreover, the company's market potential in Europe may be limited by a relatively modest expected market penetration. Overall, the risks and uncertainties surrounding Immutep's main asset, combined with the competitive landscape and unproven success of its pipeline candidates, lead to a negative outlook on the company's stock.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.